PHARMA PULSE
Thursday, April 16, 2026
Market Intelligence for Pharma Professionals
🎯 Today's Pharma PulseUpdated 57m ago
STORM Therapeutics Secures $56M Series C, Launches First‑in‑Class METTL3 Inhibitor in Phase 2
Cambridge‑based STORM Therapeutics closed a $56 million Series C round funded entirely by existing investors. The company dosed the first patient in a Phase 2 trial of its oral METTL3 inhibitor STC‑15 for sarcoma, the world’s first RNA‑modifying enzyme inhibitor to reach human trials after showing durable tumor regressions in Phase 1.
Also developing:
By the numbers: Rubicon Research acquires 85% of Arinna Lifesciences for $21M
💬 Top Pharma Social Posts

Thread by @Nicknorwitz
1/2) New research suggests GLP-1 weight loss drugs probably do NOT cause disproportionate loss of functional lean muscle. The confusion has arisen from the fact that DXA scans capture and pool a lot of different organs and tissues into the category of "Lean Mass" So a shrinking liver can get counted as "leas mass loss." But there's much more... (keep reading)

Tweet by @BradStanfieldMD
Our Rapamycin & Exercise clinical trial has just been published! The topline result? Rapamycin didn't help. Instead, it may have made things worse. Here's what we found 🧵 https://t.co/vpy9bPrGDJ https://t.co/GC6974lExP
